President Trump announced a new executive order aiming to slash prescription drug prices by 30-80%, implementing a “Most Favored Nation” policy to align US prices with the lowest worldwide prices. This action, to be signed the following morning, seeks to address the significant disparity between US and international drug costs. The policy’s effectiveness, however, faces uncertainty regarding its enforceability on the private sector, with critics questioning its feasibility and potential legal challenges. Trump’s initiative has garnered both praise and skepticism, highlighting the complexities of regulating pharmaceutical pricing.
Read More
The United States Trade Representative has issued a report citing concerns about Australia’s pharmaceutical pricing, biosecurity measures, and media bargaining code, prompting potential tariffs. Prime Minister Albanese firmly rejected negotiations on these issues, stating that compromising biosecurity is unacceptable and the pharmaceutical and media policies are non-negotiable. Opposition leader Dutton supported Albanese’s stance, while former Prime Minister Turnbull advised strength in facing potential US pressure. The US is expected to announce further tariffs, potentially impacting Australian agriculture and medicine sectors.
Read More
The Pharmaceutical Benefits Scheme (PBS), while a “world-class” program providing affordable medications to Australians, faces criticism from US pharmaceutical companies for its processes. These companies allege the PBS employs biased assessments, imposes unreasonable delays in approving new medicines, and creates unnecessary administrative hurdles. This criticism carries significant cost implications for the Australian government and raises the potential for US trade retaliation, though experts offer differing perspectives on the likelihood of such action. Despite assurances from both major Australian political parties to protect the PBS, the precedent of US tariffs on other Australian goods demonstrates the vulnerability of the system to external pressure.
Read More
In a recent WIRED interview, Mark Cuban discussed his pharmaceutical company, Cost Plus Drugs, highlighting its success in disrupting the industry by offering transparent pricing and significantly lower drug costs. Cuban claims the company has lowered prices daily for 18 months, resulting in potential billion-dollar savings for Medicare. He also commented on his move from X to Bluesky, citing Bluesky’s superior troll-blocking and engagement features, contrasting it with X’s current state under Elon Musk’s ownership. Cuban believes Bluesky offers a more genuine social networking experience.
Read More
Novo Nordisk’s recent announcement to slash US list prices of two insulin products by more than 70% is undeniably a significant event. This dramatic price reduction, while seemingly a benevolent act, is a complex issue with multiple contributing factors beyond simple corporate altruism.
The timing of this price cut is intriguing, coinciding with the Biden administration’s negotiations with pharmaceutical companies to lower Medicare drug prices. While the full effects of these negotiations won’t be felt until 2026, Novo Nordisk’s proactive move suggests a response to the broader pressure for affordability in the insulin market. It’s tempting to see this as a direct result of political pressure, and perhaps it partially is, but it’s likely more nuanced than that.… Continue reading
CVS Health, UnitedHealth Group, and Cigna filed a lawsuit against the FTC, arguing the agency’s administrative court proceedings regarding insulin pricing violate their Fifth Amendment due process rights. The companies contend the FTC’s claims, alleging a “perverse” rebate system inflates insulin costs, should be litigated in federal court, not the agency’s internal process. They argue the FTC’s structure lacks democratic accountability, deeming the process fundamentally unfair. The FTC responded that the companies’ constitutional challenge is a distraction from accusations of harming patients through inflated insulin prices. This action follows earlier recusal requests based on alleged commissioner bias.
Read More
John Q. Hosedrinker 
Matt Underwood